Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent

Authors


  • Conflicts of interest: EA has received an honorarium from and has served on the advisory board of Celgene Corp.

No abstract is available for this article.

Ancillary